hackint0sh/New-Dataset huggingface dataset:
Blood will be analyzed to check on various health indicators, like bone health markers and certain hormones, to see how they change after the meal. The difference in these health indicators between the calcium and placebo sessions will help the study team understand the impact of calcium on health after eating. This could help increase knowledge of the impact of calcium on hormones and bone health. conditions: Healthy conditions: Adult conditions: Calcium conditions: Bone Resorption conditions: Endocrine; Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized placebo crossover trial primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Investigator, participants, team distributing pills blinded to treatment arm whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 14 type: ACTUAL name: Calcium carbonate name: Placebo Control measure: Difference in GIP (gastric inhibitory peptide) area under the curve between calcium and placebo measure: Difference in GLP-1 (glucagon-like peptide 1) area under the curve between calcium and placebo measure: Difference in CTX (carboxy-terminal collagen crosslinks) area under the curve between calcium and placebo measure: Difference in P1NP (N-terminal propeptide) area under the curve between calcium and placebo measure: Difference in insulin area under the curve between calcium and placebo measure: Difference in glucose area under the curve between calcium and placebo measure: Difference in PTH (parathyroid hormone) area under the curve between calcium and placebo sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: University of Georgia Clinical and Translational Research Unit city: Athens state: Georgia zip: 30606 country: United States lat: 33.96095 lon: -83.37794 hasResults: False
nctId: NCT06383104 id: MyoLupus briefTitle: Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus. overallStatus: RECRUITING date: 2024-04-22 date: 2024-05-28 date: 2024-06-26 date: 2024-04-25 date: 2024-04-25 name: Universidad Católica San Antonio de Murcia class: OTHER briefSummary: Introduction. Systemic lupus erythematosus is an autoimmune disease. The musculoskeletal system is affected in 90% of patients. The most common manifestations are myalgias, arthralgias and arthritis.
Expected results. Improvement of knee and ankle pain intensity, functional capacity, basic mobility skills, strength, balance, agility and fatigue. conditions: System; Lupus Erythematosus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Intervention measure: Change from baseline joint pain after treatment and at 4 weeks measure: Change from baseline functional capacity after treatment and at 4 weeks measure: Change from baseline functionality after treatment and at 4 weeks measure: Change from baseline joint pain after treatment and at 4 weeks sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Universidad Católica San Antonio, Murcia status: RECRUITING city: Murcia zip: 30107 country: Spain name: RUBEN CUESTA-BARRIUSO, PhD role: CONTACT phone: +34 968278545 email: rcuesta@ucam.edu lat: 37.98704 lon: -1.13004 hasResults: False
nctId: NCT06383091 id: IRB00380938 briefTitle: Impact of Manual Therapy on Laryngeal Function Following Total Thyroidectomy acronym: Man Total Thy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Johns Hopkins University class: OTHER briefSummary: In this clinical trial, the investigators are seeking to learn if a course of voice therapy, including neck massage, stretches and pain science education in addition to voice exercise and scar massage will effectively treatment patient complaints of swallowing or voice changes after total thyroidectomy as compared to voice exercise and scar massage alone.
Complete a journal of the participant's Home Exercise Practice conditions: Total Thyroidectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is meant to be a parallel study. However, The Speech Language Pathologists will not be blinded as the Speech Pathologists are providing each regimen. If a participant in either group requires more intensive sessions or a differing regimen given the severity of complaints, the participants will receive it as per the recommendation of the Speech-Language Pathologist so as not to unblind the PI. An intent to treat analysis will be performed to accurately describe the data in the case of crossover and/or dropout. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: Anterior Neck Manual Therapy name: Pain Neuroscience Education name: Neck Stretches name: Scar massage name: Voice Exercises name: Placebo Anterior Neck Manual Therapy name: Placebo Pain Neuroscience Education name: Placebo Neck Stretches measure: Acoustic measures of voice clarity measure: Acoustic measures of speaking voice pitch measure: Acoustic measures of speaking voice quality subjectively measure: Swallowing Quality of Life as assessed by the Eating Assessment Tool - 10 measure: Laryngeal sensation measure: Scar Tethering Distance measure: Scar Quality as assessed by The Patient and Observer Scar Assessment Scale measure: Voice Quality of Life as measures by the Voice Related Quality of Life - 10 measure: Adverse Effects in the Experimental Group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Hospital city: Baltimore state: Maryland zip: 21287 country: United States name: Claire Ligon, Masters of Education role: CONTACT phone: 434-390-6387 email: cligon4@jhmi.edu name: Kristine Pietsch, Masters of Arts role: CONTACT phone: 518-461-3610 email: kteets1@jhmi.edu name: Claire Ligon, Masters of Education role: SUB_INVESTIGATOR name: Kristine Pietsch, Masters of Arts role: SUB_INVESTIGATOR name: Michelle Wilson, Masters of Science role: SUB_INVESTIGATOR lat: 39.29038 lon: -76.61219 facility: Suburban Hospital city: Bethesda state: Maryland zip: 20817 country: United States name: Claire Ligon, Masters of Education role: CONTACT phone: 434-390-6387 email: cligon4@jhmi.edu name: Vaninder Dhillon, Medical Doctor role: CONTACT phone: 925-360-5939 email: vdhillo2@jhmi.edu name: Vaninder Dhillon, Medical Doctor role: PRINCIPAL_INVESTIGATOR name: Claire Ligon, Masters of Education role: SUB_INVESTIGATOR name: Michelle Wilson, Masters of Science role: SUB_INVESTIGATOR lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06383078 id: MA-PC-II-012 briefTitle: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2027-03-01 date: 2027-12-30 date: 2024-04-25 date: 2024-04-25 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer. conditions: Efficacy and Safety studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: HR070803 name: Oxaliplatin name: Tegafur name: Folinic acid name: 5-Fluorouracil measure: 1-year Disease-free survival rate measure: Overall survival (OS) measure: Disease-free survival（DFS） sex: ALL minimumAge: 20 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06383065 id: YDU/2020/76-1007 briefTitle: Respiratory Physiotherapy in Type 2 Diabetes and Bariatric Surgery overallStatus: COMPLETED date: 2020-02-01 date: 2021-04-30 date: 2022-01-30 date: 2024-04-25 date: 2024-04-25 name: Near East University, Turkey class: OTHER briefSummary: The aim of this study is to investigate the early effects of Inspiratory Muscle Training (IMT) applied before and after bariatric surgery on respiratory function, respiratory muscle strength and functional capacity in individuals with type 2 diabetes.
The study will be conducted with 40 individuals with type 2 diabetes aged between 25-65. Individuals will be randomly assigned to the IMT (trained at 30% of maximum inspiratory pressure with an IMT threshold device) and control group. As measurement parameters, a 6-minute walk test for functional capacity, a spirometry test for respiratory function, and a portable device (Cosmed Pony FX Desktop Spirometer, USA) will be used for respiratory muscle strength. Hand grip strength will be measured with a Baseline dynamometer. All measurements will be repeated on the first day before surgery and on the fourth day before discharge after surgery. conditions: Type 2 Diabetes conditions: Bariatric Surgery Candidate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ACTUAL name: IMT Group measure: Respiratory Muscle Strength measure: Respiratory Function measure: Functional Capacity: The 6-minute walk test measure: Hand Grip Strength sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Near East University city: Nicosia country: Cyprus lat: 35.17531 lon: 33.3642 hasResults: False
nctId: NCT06383052 id: NYM032Z01 briefTitle: A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC overallStatus: RECRUITING date: 2024-04-30 date: 2024-11-30 date: 2024-11-30 date: 2024-04-25 date: 2024-04-25 name: Norroy Bioscience Co., LTD class: INDUSTRY briefSummary: 177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA. conditions: Metastatic Castration-resistant Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: 177Lu-NYM032 injection measure: Number of Patients With Dose Limiting Toxicity (DLT) measure: Maximum Tolerated Dose (MTD) sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affliated Hospital of Jiangnan University status: RECRUITING city: Wuxi zip: 214000 country: China name: Chunjing Yu role: CONTACT phone: 15312238622 email: ycj_wxd1978@163.com lat: 31.56887 lon: 120.28857 hasResults: False
nctId: NCT06383039 id: ZSoy briefTitle: Transcranial Direct Current Stimulation and Balance acronym: tDCS overallStatus: COMPLETED date: 2022-05-16 date: 2022-09-06 date: 2023-05-13 date: 2024-04-25 date: 2024-04-25 name: Zeynep Soy class: OTHER briefSummary: Postural control is an adaptive sensorimotor process involving continuous integration of sensory information from three channels. These; visual, somatosensory (proprioceptive) and vestibular senses. The study will be carried out at Istanbul Medipol University. 30 healthy individuals between the ages of 18-25 will be included. To each individual Anodal-supplementary motor area tDCS, Anodal-cerebellar tDCS, Sham tDCS applications will be cross-applied. tDCS application will take 20 minutes and each individual will receive 3 sessions in total. There will be a 72-hour rest period between sessions. Individuals assessed with Demographic Information Form for demographic information, Wii-Fit and Balance Error Scoring System for Static Balance Evaluation, Star Balance Test and Timed Get Up and Go Test for Dynamic Balance Assessment. The aim of this study is to investigate the effect of transcranial direct current stimulation applied on the supplementary motor area and cerebellum on static and dynamic balance in healthy individuals. conditions: Balance studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: All participants received 3 different interventions at different times. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants were not informed which type of current was applied. whoMasked: PARTICIPANT count: 30 type: ACTUAL name: Transcranial Direct Current Stimulation measure: Demographic Information Form measure: Wii-Fit measure: balance error scoring system measure: star excursion balance test measure: Time Up & Go Test sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Istanbul Medipol University city: Istanbul state: Beykoz country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06383026 id: PRO00047199 briefTitle: Transgender and Gender-Diverse Breast Cancer Screening Pilot overallStatus: RECRUITING date: 2024-04-17 date: 2027-12 date: 2028-02 date: 2024-04-25 date: 2024-04-25 name: Medical College of Wisconsin class: OTHER briefSummary: This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 130 type: ESTIMATED name: Breast Cancer Screening name: Survey/Interview name: Focus Group measure: Callback and Biopsy Rates after Breast Cancer Screening measure: Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Transgender and Gender Diverse Persons measure: Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening sex: ALL minimumAge: 30 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical College of Wisconsin status: RECRUITING city: Milwaukee state: Wisconsin zip: 53226 country: United States name: Chandler S Cortina, MD, MS role: CONTACT email: ccortina@mcw..edu lat: 43.0389 lon: -87.90647 hasResults: False
nctId: NCT06383013 id: BB-101-BBCBB1A briefTitle: Phase II Study of BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers overallStatus: RECRUITING date: 2024-02-29 date: 2027-12-31 date: 2028-12-31 date: 2024-04-25 date: 2024-04-25 name: Blue Blood Biotech Corp. class: INDUSTRY briefSummary: This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer. conditions: Diabetic Foot Ulcer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 96 type: ESTIMATED name: BB-101 measure: Efficacy Evaluation measure: Safety Evaluation measure: Secondary Efficacy Evaluation measure: Exploratory Objectives sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare status: RECRUITING city: Taipei country: Taiwan name: Shug-Cheng Chang, MD role: CONTACT lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06383000 id: BLZ2024MOH briefTitle: Assessment of Effectiveness of Continuous Non-invasive Haemodynamic Monitor by Compared to Invasive Blood Pressure and Pulse Oximeter Monitoring on Patients Undergoing General Anesthesia Surgeries for More Than 60 Minutes overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-25 date: 2024-04-25 name: BLZ Technology (Wuhan) Co.,Ltd class: INDUSTRY briefSummary: The goal of this observational study is to assess whether the continuous non-invasive haemodynamic monitor MOH200 (measuring blood pressure as well as pulse rate) is effective or not in people undergoing general anesthetic surgeries for more than 60 minutes with planned invasive blood pressure and pulse oximeter monitoring.
Participants will be asked to be applied with MOH200 monitoring while IBP monitoring and pulse oximeter are applied. And after 30 minutes of the surgery, researchers will monitor the adverse effects occurred on the skin of participants to assess the safety of MOH200. conditions: General Anesthesia conditions: Blood Pressure conditions: Pulse Rate conditions: Arterial Line studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED measure: Continuous Non -invasive Blood Pressure Measurement from MOH200 measure: Invasive Blood Pressure Measurement from Arterial Line measure: Pulse Rate Measurement from MOH200 measure: Pulse Rate Measurement from Pulse Oximeter measure: The Occurrence of Pressure Pores sex: ALL minimumAge: 4 Years maximumAge: 80 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06382974 id: 3-3-14 briefTitle: Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-03 date: 2024-04-25 date: 2024-04-25 name: Cairo University class: OTHER briefSummary: This case series study aims to evaluate the local effects of Atorvastatin (which belongs to the family of lipid-lowering drugs, known as statins) combined with β-TCP (which is a synthetic osteoconductive bone graft), on the volume of the residual bone defects and on hastening the bone regeneration after radicular jaw cyst enucleation using CBCT-based volumetric analysis to calculate the shrinkage rate of these defects. conditions: Infection conditions: Bone Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A case series study. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Cyst enucleation and bone grafting measure: Shrinkage Rate measure: Inflammation sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Cairo University city: Cairo country: Egypt role: CONTACT phone: 23634965 email: surgery@dentistry.cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06382961 id: SZUS_231101 briefTitle: Postoperative Dexmedetomidine in Prevention of Postoperative Delirium overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-11 date: 2024-03-06 date: 2024-04 date: 2024-04-25 date: 2024-04-25 name: Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. class: INDUSTRY name: Shenzhen People's Hospital name: Dongyuan People's Hospital name: Kunming Children's Hospital briefSummary: The goal of this clinical trial is to learn how postoperative infusion of dexmedetomidine would influence postoperative delirium in elderly patients undergoing lung surgery. The main questions it aims to answer are :
2. Postoperative visit twice a day for at least seven days conditions: Delirium in Old Age conditions: Anesthesia; Adverse Effect studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 287 type: ACTUAL name: Dexmedetomidine injection name: Sufentanil injection measure: Incidence of postoperative delirium measure: Incidence of postoperative nausea and vomiting measure: incidence of postoperative complications measure: Pain intensities sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Kunming Children's Hospital city: Kunming state: Yunnan zip: 650100 country: China lat: 25.03889 lon: 102.71833 hasResults: False
nctId: NCT06382948 id: MedOPP545 id: 2024-512926-27-00 type: CTIS briefTitle: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. acronym: ADELA overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-09 date: 2028-04 date: 2024-04-24 date: 2024-04-26 name: MedSIR class: OTHER name: Stemline Therapeutics, Inc. briefSummary: This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.
The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival.
nctId: NCT06382935 id: 34-24 briefTitle: Impact of Non-surgical Periodontal Treatment of miRNome overallStatus: RECRUITING date: 2024-04-20 date: 2024-09-22 date: 2024-10-15 date: 2024-04-24 date: 2024-04-24 name: University of Catania class: OTHER briefSummary: A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment by means of minimally invasive approach MINST or Q-SI (quadrantwise) approach in subjects with periodontitis on miRNome in gingival crevicular fluid conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Non-surgical periodontal treatment Subgingival biofilm ultrasonic debridement with MINST or Q-SI primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Sealed envelopes whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Probin Pocket Depth reduction measure: Probing Pocket Depth sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AOU Policlinico G. Rodolico status: RECRUITING city: Catania zip: 95124 country: Italy name: Gaetano Isola, DDS role: CONTACT phone: 0953785652 email: gaetano.isola@unict.it lat: 37.49223 lon: 15.07041 hasResults: False
nctId: NCT06382922 id: PAPAML022019 briefTitle: Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy overallStatus: RECRUITING date: 2023-03-29 date: 2024-07-30 date: 2025-06-01 date: 2024-04-24 date: 2024-04-29 name: University of Rome Tor Vergata class: OTHER briefSummary: In previous retrospective study (SEIFEM 2016 study) the investigators evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of mold active primary antifungal prophylaxis (PAP) in a "real life" setting of acute myeloid leukemia (AML )patients receiving intensive consolidation therapy. All cases of proven/probable IA, observed during consolidation chemotherapy in adult and pediatric AML patients between 2011 and 2015, were retrospectively collected in a multicenter study involving 38 Italian hematologic centers. The investigators observed 56 (2.2%) cases of IA \[43 probable (1.7%) and 13 proven (0.5%)\]. The overall mortality rate and the mortality rate attributable to IA (AMR) on day 120 were 16% and 9%, respectively. In multivariate analysis, parameters that influenced the outcome were age ≥60 years and treatment with high doses of cytarabine (HDAC).